Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.

Ricceri, F; Pescitelli, L; Lazzeri, L; Di Cesare, A; Prignano, F

Ricceri, F; Pescitelli, L; Lazzeri, L; Di Cesare, A; Prignano, F.

Afiliación

Ricceri F; Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125, Florence, Italy.
Pescitelli L; Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125, Florence, Italy.
Lazzeri L; Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125, Florence, Italy.
Di Cesare A; Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125, Florence, Italy.
Prignano F; Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125, Florence, Italy.

J Eur Acad Dermatol Venereol ; 31(11): e486, 2017 11.

Article en En | MEDLINE | ID: mdl-28449189

Asunto(s)

Hepatitis B; Psoriasis; Adalimumab; Estudios de Cohortes; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Hepatitis B Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2017 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google